Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity
Christopher Hite, Executive Vice President and Chairman of Partnering at Royalty Pharma plc
(NASDAQ:RPRX)
, disclosed in a Form 4 filed on August 19, 2026, the sale of 100,000 Class A Ordinary Shares and a charitable donation of 16,800 Class A Ordinary Shares on August 18-19, 2026.
Key Highlights
- 100,000 shares sold: On August 18, 2026, Hite sold 100,000 Class A Ordinary Shares at a weighted average price of $59.9725 per share, with individual transaction prices ranging from $59.68 to $60.42.
- 10b5-1 trading plan: All sales were executed under a 10b5-1 plan adopted by Hite on March 20, 2026, as stated in the filing.
- Charitable donation: On August 19, 2026, Hite gifted 16,800 Class A Ordinary Shares to Lehigh University without consideration, recorded with transaction code G.
- Post-transaction ownership: After these transactions, Hite indirectly owns 370,401 Class A Ordinary Shares via SCH Investment Partners LLC and directly holds 23,200 Class A Ordinary Shares.
- Additional exchangeable interests: Hite-controlled family vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares.
Details of Christopher Hite’s August 2026 Royalty Pharma Share Transactions
Per the SEC Form 4 filed on August 19, 2026, Christopher Hite, EVP and Chairman of Partnering at Royalty Pharma plc, reported two transactions involving the company’s Class A Ordinary Shares occurring on August 18 and 19, 2026. The filing was signed by Sean Weisberg as Attorney-in-Fact for Hite.
The first transaction on August 18, 2026, involved the sale of 100,000 Class A Ordinary Shares held indirectly through SCH Investment Partners LLC. The weighted average sale price was $59.9725 per share, with individual prices ranging from $59.68 to $60.42. The filing states Hite will provide detailed share sale prices upon written request. Following this sale, SCH Investment Partners LLC retained 370,401 Class A Ordinary Shares on Hite’s behalf. The sales were conducted under a Rule 10b5-1 trading plan adopted on March 20, 2026.
The second transaction on August 19, 2026, was a charitable gift of 16,800 Class A Ordinary Shares to Lehigh University at no cost (transaction code G). After this gift, Hite’s direct holdings amounted to 23,200 Class A Ordinary Shares. Additionally, the filing reveals that family vehicles controlled by Hite hold limited partnership interests exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Summary of Disclosures
The filing detailed the sale of 100,000 Class A Ordinary Shares via a pre-established 10b5-1 plan and a charitable donation of 16,800 shares to Lehigh University, along with Hite’s resulting direct and indirect ownership stakes in Royalty Pharma plc.
